Introduction {#s2}
============

NTM are ubiquitous organisms, commonly found in soil and water, that rarely cause human disease. However, in people with underlying structural lung disease such as bronchiectasis, poor sputum clearance as found in cystic fibrosis (CF), or underlying immunodeficiency they do have pathogenic potential. In some instances, lung disease occurs without identifiable underlying "risk factors". Concern has been expressed that the incidence of pulmonary NTM disease is on the rise globally, with Japan having one of the highest incidence rates \[[@C1]--[@C8]\]. This is probably multifactorial, especially in patients with CF, with contributions from better diagnostics, increased surveillance sampling and a dramatic increase in life expectancy \[[@C9]--[@C11]\].

Despite optimised antibiotic treatment, sputum clearance is difficult to achieve and highly variable in patients with pulmonary NTM disease. Based on current American Thoracic Society (ATS)/Infectious Disease Society of America (IDSA) recommendations, multidrug treatment regimens of 1--2-years duration yield sputum conversion rates of 54--87% \[[@C12]--[@C17]\]. Sputum conversion rates are lower in those previously treated or in patients infected with macrolide-resistant species \[[@C14], [@C18]\]. The recurrence rate after successful treatment with clarithromycin-containing regimens ranges between 20% and 44% \[[@C14]--[@C17], [@C19]\]. Many antibiotics used in the treatment of pulmonary NTM disease may have severe adverse effects ([table 1](#TB1){ref-type="table"}) \[[@C10]\], resulting in frequent treatment interruptions and a high cost from additional investigations and the management of side-effects. \[[@C20]\].

###### 

Common adverse effects of antibiotics used to treat NTM infections in patients with CF^\#^

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Antibiotic (delivery route)**                    **Common adverse effects**                                                                                        **Suggested monitoring**
  -------------------------------------------------- ----------------------------------------------------------------------------------------------------------------- ------------------------------------
  **Amikacin (intravenous; intramuscular)^¶^**       Nephrotoxicity\                                                                                                   Trough levels\
                                                     Auditory-vestibular toxicity (tinnitus, high-frequency hearing loss)                                              Serum creatinine

  **Amikacin (nebulisation)^¶^**                     None described                                                                                                    

  **Azithromycin (oral)**^+^                         Nausea, vomiting, diarrhoea\                                                                                      Symptoms\
                                                     Auditory-vestibular toxicity\                                                                                     Audiology\
                                                     Prolonged QTc                                                                                                     ECG

  **Bedaquiline (oral)^¶^**                          Headaches, dizziness, joint aches\                                                                                Symptoms\
                                                     Prolonged QTc\                                                                                                    ECG\
                                                     Liver enzyme derangement                                                                                          LFT

  **Cefoxitin (intravenous)^¶^**                     Fever, rash\                                                                                                      Symptoms\
                                                     Eosinophilia, anaemia, leukopenia, thrombocytopenia\                                                              FBC
                                                     Interference with serum creatinine measurement                                                                    

  **Clofazimine (oral)^¶^**                          Discoloration of skin or sclera\                                                                                  Symptoms
                                                     Enteropathy (can mimic pancreatic insufficiency), nausea and vomiting                                             

  **Ethambutol (oral)**^+^                           Optic neuritis                                                                                                    Symptoms, colour vision and acuity

  **Imipenem (intravenous)^¶^**                      Nausea, vomiting, diarrhoea\                                                                                      Symptoms\
                                                     Hepatitis                                                                                                         LFT

  **Linezolid (oral)^¶^**                            Anaemia, leukopenia, thrombocytopenia\                                                                            FBC\
                                                     Peripheral neuropathy, optic neuritis                                                                             Symptoms/clinical

  **Minocycline (oral)^¶^**                          Photosensitivity, skin discolouration\                                                                            Symptoms
                                                     Nausea, vomiting, diarrhoea\                                                                                      
                                                     Vertigo                                                                                                           

  **Moxifloxacin (oral)^¶^**                         Nausea, vomiting, diarrhoea\                                                                                      Symptoms\
                                                     Insomnia, agitation, anxiety\                                                                                     ECG
                                                     Tendonitis\                                                                                                       
                                                     Photosensitivity\                                                                                                 
                                                     Prolonged QTc                                                                                                     

  **Rifabutin (oral)**^+^                            Leukopenia, anterior uveitis (when combined with clarithromycin), flu-like symptoms (polyarthralgia or myalgia)   Symptoms\
                                                                                                                                                                       FBC

  **Rifampicin (oral)**^+^                           Orange discolouration of bodily fluids, fever, chills, nausea, vomiting, diarrhoea\                               Symptoms\
                                                     Hepatitis\                                                                                                        LFT\
                                                     Thrombocytopenia\                                                                                                 FBC\
                                                     Renal failure\                                                                                                    EUC
                                                     Increased drug metabolism                                                                                         

  **Streptomycin (intravenous, intramuscular)^¶^**   Nephrotoxicity                                                                                                    Trough levels, serum creatinine

  **Tigecycline (intravenous)^¶^**                   Nausea, vomiting, diarrhoea\                                                                                      Symptoms\
                                                     Pancreatitis\                                                                                                     Serum amylase, lipase\
                                                     Hypoproteinaemia, bilirubinaemia                                                                                  LFT plus albumin
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

LFT: liver function test; FBC: full blood count; EUC: electrolytes, urea and creatinine; QTc: corrected QT interval. ^\#^: based on United States CF Foundation (USCF) and European CF society (ECFS) consensus recommendations \[46\]; **^¶^**: primarily used for *Mycobacterium* *abscessus* complex; ^+^: primarily used for MAC. Reproduced from \[10\] with permission.

Surgery has been used as adjuvant therapy in the treatment of NTM pulmonary disease \[[@C12], [@C21]\], to effect higher rates of cure in patients with focal lung involvement. Increased cure and reduced relapse rates have been demonstrated with the use of lung surgery in the treatment of multidrug-resistant tuberculosis (MDR-TB). A recent meta-analysis of the role of surgery as an adjuvant therapy demonstrated that partial lung resections, but not pneumonectomy, were associated with improved treatment success (cure and completion) (OR 3.0; 95% CI 1.5--5.9; I^2^~R~ 11.8%), and that a good outcome was more likely when surgery was performed after initial culture conversion \[[@C22]\]. We critically reviewed the treatment outcomes achieved with surgical management of pulmonary NTM disease.

Studies undertaken in the pre- and post-clarithromycin era {#s2a}
----------------------------------------------------------

Studies showed that combined medical and surgical management of NTM had low mortality with high rates of sputum conversion \[[@C23]--[@C27]\], which was often difficult to achieve with antibiotic treatment alone. With the addition of clarithromycin (in the late 1990s) the success rate from antibiotic treatment increased \[[@C12]--[@C17]\]; however, treatment failure rates with clarithromycin-resistant species or with acquired-clarithromycin resistance during treatment remained high. Studies undertaken after the clarithromycin era demonstrated benefit from lung surgery in select patient groups only \[[@C19], [@C28]--[@C31]\].

[Table 2](#TB2){ref-type="table"} presents an overview of identified studies where surgical intervention was performed and describes the characteristics of the patient cohorts selected for surgery. Other studies where surgery was performed in a small number of the overall cohort did not have sufficiently detailed information about the surgery cases to be included in the table \[[@C32], [@C33]\]. None of the studies included children and there was a female predominance. Most patients had bronchiectasis and/or lung cavities visible on a chest radiograph or computed tomography scan. A history of cigarette smoking (range 18--97%) or previous pulmonary TB (range 8--26%) was common in the studies where this was mentioned \[[@C30], [@C31], [@C34]--[@C37]\]. Underlying immunodeficiency was uncommon and absent in six studies where this was mentioned \[[@C19], [@C28], [@C29], [@C38]--[@C40]\]. Low body mass index (BMI) was common in studies where immunodeficiency was reported \[[@C29]--[@C31], [@C37], [@C40], [@C41]\], and was identified as a predictor of poor prognosis in one study \[[@C37]\]. Most studies included patients with MAC disease and were performed in the USA and Japan. None of the studies included patients with CF.

###### 

Overview of patient characteristics in NTM lung surgery studies performed to date

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **First author  \[ref.\]**                      **Study year(s),  location**   **Patients  n**   **Median (range)  age years**     **Females %**   **NTM species**                      **Lung involvement and/or comorbidities**
  ----------------------------------------------- ------------------------------ ----------------- --------------------------------- --------------- ------------------------------------ -------------------------------------------
  **Studies without clarithromycin**                                                                                                                                                      

   E[lkadi]{.smallcaps} \[23\]                    1962--1973 Missouri, USA       48                48 (20--72)                       33%             *M.* *kansasii* 54%\                 Lung cavities 77%
                                                                                                                                                     *M.* *intracellulare* 42%\           
                                                                                                                                                     Rapid grower 2%                      

   P[omerantz]{.smallcaps} \[36\]                 1983--1990 Colorado, USA       38                50 (33--39)                       68%             MAC 87%\                             Previous lobectomy 18%\
                                                                                                                                                     *M.* *kansaii* 3%\                   Previous TB 8%\
                                                                                                                                                     *M.* *chelonae* 3%\                  Bronchopleural fistula 8%\
                                                                                                                                                     *M.* *xenopi* 3%                     Chest radiation 8%

   O[no]{.smallcaps} \[35\]                       1991--1996 Wakayama, Japan     8                 50 (36--72)                       50%             MAC 100%                             Cigarette smoker 25%\
                                                                                                                                                                                          Bronchiectasis, 25%\
                                                                                                                                                                                          Previous TB 25%\
                                                                                                                                                                                          Sjögren\'s syndrome 13%

   N[elson]{.smallcaps} \[38\]                    1989--1997 Texas, USA          28                Mean±[sd]{.smallcaps} 50±11       25%             MAC 100%                             Almost all were smokers\
                                                                                                                                                                                          67% \>20% below weight standard\
                                                                                                                                                                                          No immunocompromised

   S[hiraishi]{.smallcaps} \[34\]                 1979--1996 Tokyo, Japan        33                50 (30--69)                       48%             MAC 100%                             Cigarette smoker 97%\
                                                                                                                                                                                          Bronchiectasis 21%\
                                                                                                                                                                                          Cavity 64%; nodule 3%\
                                                                                                                                                                                          Previous TB 9%\
                                                                                                                                                                                          Pneumonia 9%

  **Studies incorporating clarithromycin**                                                                                                                                                

   S[hiraishi]{.smallcaps} \[28\]                 1993--2001 Kyoto, Japan        21                56 (27--67)                       48%             MAC 100%                             Bronchiectasis 10%\
                                                                                                                                                                                          Cavity 76%; nodule 10%\
                                                                                                                                                                                          Destroyed lung 5%\
                                                                                                                                                                                          No immunocompromised

   S[hiraishi]{.smallcaps} \[29\]                 1983--2002 Tokyo, Japan        11                57 (43--69)                       73%             MAC 91%\                             Multiple cavities 55%\
                                                                                                                                                     *M.* *abscessus* 9%                  Destroyed lung 46%\
                                                                                                                                                                                          Bilateral disease 36%\
                                                                                                                                                                                          No immunocompromised

   W[atanabe]{.smallcaps} \[39\]                  1990--2005 Tokyo, Japan        22                54 (30--77)                       68%             MAC 100%                             Bronchiectasis predominant 64%\
                                                                                                                                                                                          Cavitary predominant 36%\
                                                                                                                                                                                          No immunocompromised

   M[itchell]{.smallcaps} \[43\]                  1983--2006 Colorado, USA       236               54 (23--77)                       83%             MAC 80%\                             Focal bronchiectasis 55%\
                                                                                                                                                     *M.* *abscessus* 14%                 Cavitary lung disease 29%\
                                                                                                                                                                                          Mixed pattern 9%\
                                                                                                                                                                                          Prior thoracic surgery 20%

   K[oh]{.smallcaps} \[40\]                       2002--2007 Seoul, Korea        23                45 (24--66)                       70%             MAC 43%\                             Cavities 70%\
                                                                                                                                                     *M.* *abscessus* 52%\                Bronchiectasis 30%\
                                                                                                                                                     *M.* *xenopi* 4%                     No immunocompromised

   [van]{.smallcaps} I[ngen]{.smallcaps} \[19\]   2000--2009 Holland             8                 52 (41--59)                       25%             MAC 88%\                             Cavitary 62%\
                                                                                                                                                     *M.* *xenopi* 12%                    Mixed pattern 25%\
                                                                                                                                                                                          Bronchiectasis 13%\
                                                                                                                                                                                          No immunocompromised

   Y[u]{.smallcaps} \[30\]                        2004--2009 Colorado, USA       128               59 (34--81)                       96%             MAC 88%\                             Bronchiectasis 95%\
                                                                                                                                                     *M.* *abscessus* or *chelonae* 10%   Cigarette smoker 16%\
                                                                                                                                                                                          Cavitary disease 3%\
                                                                                                                                                                                          Mixed pattern 2%\
                                                                                                                                                                                          Prior thoracic procedure 10%

   J[arand]{.smallcaps} \[41\]^\#^                2001--2008\                    24                Mean±[sd]{.smallcaps} 57.7±11.1   83%             *M.* *abscessus* 100%                Localised bronchiectasis 86%\
                                                  Alberta, Canada                                                                                                                         Coexisting/previous MAC 54.2%\
                                                                                                                                                                                          Cavitary disease 37%\
                                                                                                                                                                                          Previous smokers 23%\
                                                                                                                                                                                          Previous TB 8.3%

   S[hiraishi]{.smallcaps} \[31\]                 2007--2011 Tokyo, Japan        60                50 (20--72)                       68%             MAC 92%\                             Bronchiectasis 48%\
                                                                                                                                                     *M.* *abscessus* 5%\                 Cavities 42%\
                                                                                                                                                     *M.* *gordonae* 2%\                  Cigarette smoker 18%\
                                                                                                                                                     *M.* *xenopi* 2%                     Mixed pattern 7%\
                                                                                                                                                                                          Diabetes mellitus 6.7%

   A[sakura]{.smallcaps} \[37\]                   1994--2015 Yokohama, Japan     125               60 (IQR 49--66)\                  53%             MAC 80%\                             Cavities 70%; nodules 98%\
                                                                                                   \                                                 *M.* *intracellulare* 8%\            Bronchiectasis 89%\
                                                                                                                                                     *M.* *abscessus* 5%\                 Cigarette smoker 29%\
                                                                                                                                                     *M.* *kansasii* 3%\                  Old TB 26%,\
                                                                                                                                                     Others 5%                            COPD 10%\
                                                                                                                                                                                          Diabetes mellitus 10%
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*M.* *kansasii*: *Mycobacterium kansasii*; *M.* *intracellulare*: *Mycobacterium intracellulare*; *M. chelonae*: *Mycobacterium chelonae*; *M.* *xenopi*: *Mycobacterium xenopi*; *M. abscessus*: *Mycobacterium abscessus*; *M.* *gordonae*: *Mycobacterium gordonae*; IQR: interquartile range; COPD: chronic obstructive pulmonary disease. ^\#^: compared combined antibiotic and surgical treatment with antibiotic treatment alone.

Indications for surgery {#s3}
=======================

According to ATS/IDSA guidelines, surgery should only be considered in select patients who meet the diagnostic criteria for pulmonary NTM disease \[[@C12]\]. Specifically, they need to have localised disease deemed amenable to resection and be judged to have adequate pulmonary reserve \[[@C12]\]. Generally, the indications for surgery fall into three categories: 1) removing a disease focus to optimise the chances of cure; 2) removing a destroyed part of the lung for symptomatic relief or prevention of a catastrophic bleed; and 3) limiting the rate of disease progression in cases with a poor response to medical treatment.

N[elson]{.smallcaps} *et al*. \[[@C38]\] indicated that in the pre-clarithromycin era, most of the surgical treatments were used at an earlier stage of infection in conjunction with medical therapy to try and cure the NTM disease. However, since newer generation macrolides (specifically clarithromycin) became available, surgery has predominantly been used in the setting of treatment failure (71% of cases) \[[@C38]\]. Poor response to antibiotic treatment has been defined as the lack of sputum clearance and/or ongoing features of active disease and progressive lung destruction on imaging. Clarithromycin susceptibility is an important factor when considering surgical resection, given that clarithromycin-resistant strains have significantly reduced sputum conversion rates (∼25%) with antibiotic therapy compared with susceptible strains (∼85%) \[[@C14]\].

Excessive haemoptysis can be lethal and is the most common symptom leading to surgical resection. Intractable cough is another symptomatic indication for surgery if this has a major negative impact on a patient\'s quality of life. In these instances, surgical intervention seeks to provide symptom relief or prevent a life-threatening complication, irrespective of clinical cure. The third indication is to use surgery to protect the unaffected or residual lung by removal of an intractable disease focus that remains a source of infected secretions with risk of intrapulmonary spread \[[@C42]\].

Surgical options {#s4}
================

All the surgical interventions were conducted under general anaesthesia with frequent use of a double lumen endobronchial tube. Surgery duration ranged from 1 h to 8 h and blood loss from 10 mL to more than 3 litres, depending on the types of surgical resections performed and the complications encountered \[[@C28], [@C29], [@C35], [@C37], [@C38], [@C40]\]. Either a postero- or antero-lateral thoracotomy approach was used, depending on anticipated pleural adhesions. Conversion from thoracoscopic to open surgery occurred when extrapleural dissection was required or because of concerns regarding underlying vital structures. Pre-operative airway toilet using bronchoscopy was selectively used to reduce the infected secretion burden in the airways and surgeons needed to be vigilant to avoid spillage of infected debris within the pleural space or around the wound site. This type of surgery is best carried out in specialist centres with considerable experience in infectious lung surgery \[[@C42]\]. Some centres involved multidisciplinary teams consisting of surgeons, dieticians, respiratory and infectious diseases physicians specialising in NTM infections in decision making \[[@C43]\].

[Table 3](#TB3){ref-type="table"} summarises the indication for and type of surgery performed for pulmonary NTM disease. Lobectomies and segmentectomies were the most common procedures performed. [Table 4](#TB4){ref-type="table"} summarises the outcomes following surgical intervention.

###### 

Indication, type and complications of surgery performed for pulmonary NTM disease

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **First author \[ref.\]**                       **Patients n**   **Surgical indications**                        **Type of surgery**                   **Hospital stay**         **Complications**
  ----------------------------------------------- ---------------- ----------------------------------------------- ------------------------------------- ------------------------- ------------------------------------------
  **Studies without clarithromycin**                                                                                                                                               

   E[lkadi]{.smallcaps} \[23\]\                   48               Medical treatment failure                       Lobectomy 67%\                        2.4--4 months^\#^         Total=13%\
  \                                                                                                                Segmentectomy 21%\                                               Bronchopleural fistula 4%\
                                                                                                                   Pneumonectomy 6%\                                                Wound dehiscence 4%\
                                                                                                                   Wedge resection 4%\                                              Infection 2%\
                                                                                                                   Extrapleural plombage 2%                                         Haemorrhage 2%

   P[omerantz]{.smallcaps} \[36\]\                38               Localised disease with complications            Lobectomy 59%\                        Not reported              Total=50%\
  \                                                                                                                Pneumonectomy 41%\                                               Bronchopleural fistula 21%^¶^\
                                                                                                                   Both (7%)                                                        Prolonged air leak 11%\
                                                                                                                                                                                    Respiratory failure 5%\
                                                                                                                                                                                    Wound dehiscence 3%\
                                                                                                                                                                                    Pericardial effusion 3%\
                                                                                                                                                                                    Horner\'s syndrome 3%

   O[no]{.smallcaps} \[35\]\                      8                Medical treatment failure Persistent symptoms   Lobectomy 75%\                        Not reported              None reported
  \                                                                                                                 +partial resection 25%                                         

   N[elson]{.smallcaps} \[38\]                    28               Medical treatment failure\                      Partial resection 71%\                Not reported              Total=32%\
                                                                   Significantly destroyed lung\                   Pneumonectomy 29%                                                Bronchopleural fistula 4%\
                                                                   Severe haemoptysis                                                                                               Prolonged air leak 14%\
                                                                                                                                                                                    Atelectasis requiring bronchoscopy 4%\
                                                                                                                                                                                    Severe post-thoracotomy pain 4%\
                                                                                                                                                                                    Death due to post-operative MI 4%

   S[hiraishi]{.smallcaps} \[34\]                 33               Symptomatic localised disease                   Lobectomy 79%\                        Not reported              Total=18%\
                                                                                                                   Segmentectomy 15%\                                               Bronchopleural fistula 3%\
                                                                                                                   Pneumonectomy 3%\                                                Residual pleural space 15%
                                                                                                                   Wedge resection 3%                                              

  **Studies incorporating clarithromycin**                                                                                                                                         

   S[hiraishi]{.smallcaps} \[28\]                 21               Medical treatment failure or drug intolerance   Lobectomy 76%\                        Not reported              Total=29%\
                                                                                                                    Two lobes 5%\                                                   Bronchopleural fistula 10%\
                                                                                                                   Pneumonectomy 14% (90% right sided)                              Prolonged air leak 4%\
                                                                                                                                                                                    Residual pleural space 10%\
                                                                                                                                                                                    Pneumonia 4%

   S[hiraishi]{.smallcaps} \[29\]                 11               Multiple cavities or total lung destruction     Pneumonectomy 100%                    Not reported              Total=45%\
                                                                                                                                                                                    Bronchopleural fistula 27%\
                                                                                                                                                                                    Empyema 9%\
                                                                                                                                                                                    ARDS 9%

   W[atanabe]{.smallcaps} \[39\]                  22               Medical treatment failure\                      Lobectomy 64% ^+^\                    Not reported              Total=9%\
                                                                   Persistent symptoms                              Two lobes 5%^+^\                                                Residual pleural space 5%\
                                                                                                                   Partial lung resection 27%^+^\                                   Home oxygen for 2 months 5%
                                                                                                                   Segmentectomy 18%^+^\                                           
                                                                                                                   Wedge resection 27%^+^\                                         
                                                                                                                   Multiple resections 45%                                         

   M[itchell]{.smallcaps} \[43\]                  236              Medical treatment failure\                      Lobectomy 48%\                        Not reported              Total=19%\
                                                                   Focal persistent lung damage                    Segmentectomy 21%\                                               Bronchopleural fistula 4%\
                                                                                                                   Pneumonectomy 17%\                                               Prolonged air leak 4%\
                                                                                                                   Mixed procedures 15%                                             Respiratory failure/pneumonia 3%\
                                                                                                                                                                                    Post-operative bleeding 2%\
                                                                                                                                                                                    Wound dehiscence 1%\
                                                                                                                                                                                    ARDS 1%\
                                                                                                                                                                                    Atrial fibrillation 4%

   K[oh]{.smallcaps} \[40\]                       23               Medical treatment failure 48%\                  Lobectomy 70%\                        9 days (IQR 6--15 days)   Total=35%\
                                                                   Remaining cavity relapse risk 35%\               Two lobes 9%\                                                   Bronchopleural fistula 9%\
                                                                   Persistent symptoms 17%                          Two sides 13%\                                                  Prolonged air leak 9%\
                                                                                                                   Segmentectomy 13%\                                               Pneumonia 13%\
                                                                                                                   Pneumonectomy 17%                                                Wound dehiscence 4%\
                                                                                                                                                                                    Pneumonectomy syndrome 4%

   [van]{.smallcaps} I[ngen]{.smallcaps} \[19\]   8                Treatment failure\                              Lobectomy 63%\                        Not reported              Total=63%\
                                                                   Infected destroyed lung                          Two lobes 13%\                                                  Pneumothorax 38%\
                                                                                                                   Wedge resection 13%\                                             Atelectasis requiring bronchoscopy 13%\
                                                                                                                   Pneumonectomy 25%                                                Respiratory distress 13%\
                                                                                                                                                                                    Pneumonia 13%

   Y[u]{.smallcaps} \[30\]                        134              Localised disease ±cavitation\                  Lobectomy 100%\                       3 days (1--15 days)       Total=8%\
                                                                   Medical treatment failure\                       Middle 59%\                                                     Prolonged air leak 4%\
                                                                   Persistent symptoms                              Lingulectomy 41%                                                Wound infection 1%\
                                                                                                                                                                                    Atelectasis 1%\
                                                                                                                                                                                    Pleural effusion 1%\
                                                                                                                                                                                    Atrial fibrillation 1%

   J[arand]{.smallcaps} \[41\]                    24               Localised bronchiectasis 86%\                   Lobectomy 83%\                        Not reported              Total=25%\
                                                                   Cavitary disease 37%\                           Pneumonectomy 21%\                                               Haemorrhage 4%\
                                                                   Haeptysis 11%                                   Segmentectomy 10%\                                               Bronchopleural fistulae 4%\
                                                                                                                   Wedge resection 3%                                               Wound infection 4%\
                                                                                                                                                                                    Brachial plexus injury 4%\
                                                                                                                                                                                    Frozen shoulder 4%\
                                                                                                                                                                                    Respiratory failure/death 4%

   S[hiraishi]{.smallcaps} \[31\]                 60               Medical treatment failure 87%\                  Lobectomy 90%\                        Not reported              Total=12%\
                                                                   Persistent symptoms 10%\                         Two lobes 5%\                                                   Prolonged air leak 6%\
                                                                   Secondary infection 3%                          Segmentectomy 7%\                                                Atelectasis 3%\
                                                                                                                   Pneumonectomy 2%\                                                Respiratory failure 1%\
                                                                                                                   Wedge resections 3%                                              Haemorrhage 1%\
                                                                                                                                                                                    Atrial fibrillation 1%

   A[sakura]{.smallcaps} \[37\]                   125              Medical treatment failure 56%\                  Lobectomy 88%\                        Not reported              Total=22%\
                                                                   Cavities; severe bronchiectasis 29%\             Two lobes 10%\                                                  Bronchopulmonary fistula 6%\
                                                                   Persistent symptoms 15%                         Pneumonectomy 25%\                                               Bronchopleural fistula 2%\
                                                                                                                   Segmentectomy 11%\                                               Prolonged air leak 1%\
                                                                                                                   Wedge resection 2%                                               Wound dehiscence 1%\
                                                                                                                                                                                    Pneumonia or empyema 7%\
                                                                                                                                                                                    Bronchial stenosis 1%\
                                                                                                                                                                                    Diaphragmatic hernia 1%\
                                                                                                                                                                                    Left atrial rupture 1%
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

MI: myocardial infarction; ARDS: acute respiratory distress syndrome. ^\#^: patients were kept in hospital until sputum conversion; ^¶^: 15% of bronchopleural fistula occurred post-right pneumonectomy; ^+^: primarily as 45% of this cohort had multiple resections.

###### 

Pre- and post-surgical treatment with sputum clearance, relapse and mortality (early and total)

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **First author \[ref.\]**                       **Patients n**   **NTM species**                      **Pre-surgery antibiotics**\                                                                **Post-surgery antibiotics**\                                     **Follow up duration**^\#^,^¶^   **Sputum conversion immediately post-surgery**        **Relapse**                       **Mortality early and total**
                                                                                                        **% on antibiotics; duration; macrolide; % sputum clearance**                               **% on antibiotics; duration**                                                                                                                                                             
  ----------------------------------------------- ---------------- ------------------------------------ ------------------------------------------------------------------------------------------- ----------------------------------------------------------------- -------------------------------- ----------------------------------------------------- --------------------------------- -------------------------------
  **Studies without clarithromycin**                                                                                                                                                                                                                                                                                                                                                           

   E[lkadi]{.smallcaps} \[23\]                    48               *M.* *kansasii* 54%\                 100%; 1--22 months; no clarithromycin;\                                                     Up to 9 months or until sputum conversion                         Not reported                     85.4%\                                                Not reported                      None\
                                                                   *M.* *intracellulare* 42%\           54%                                                                                                                                                                                            With additional antibiotics 100%                                                        and\
                                                                   Rapid grower 2%                                                                                                                                                                                                                                                                                                             None

   P[omerantz]{.smallcaps} \[36\]                 38               MAC 87%\                             100%; 3 months; no clarithromycin;\                                                         Not reported                                                      Not reported                     Not reported                                          Not reported                      2.6%\
                                                                   *M.* *kansaii* 2.6%\                 32%                                                                                                                                                                                                                                                                                    and\
                                                                   *M.* *chelonae* 2.6%\                                                                                                                                                                                                                                                                                                       21%
                                                                   *M.* *xenopi* 2.6%                                                                                                                                                                                                                                                                                                          

   O[no]{.smallcaps} \[35\]                       8                MAC 100%                             62.5%; 8.1 months (1--30 months); no clarithromycin;\                                       Nil treatment post-operatively                                    20 months^\#^ (4--56)            100%                                                  13% 6 months                      None\
                                                                                                        12.5%                                                                                                                                                                                                                                                                                  and\
                                                                                                                                                                                                                                                                                                                                                                                               None

   N[elson]{.smallcaps} \[38\]                    28               MAC 100%                             100%; 1 year (1--6 years); 61% had clarithromycin;\                                         100%; up to 12 months                                             39 months^\#^                    \>90% 3 months after surgery: 93% (of those alive)    4% 2 years                        7%\
                                                                                                        50%                                                                                                                                                                                                                                                                                    and\
                                                                                                                                                                                                                                                                                                                                                                                               14%^+^

   S[hiraishi]{.smallcaps} \[34\]                 33               MAC 100%                             85%; 8 months (1--64 months);  4% had clarithromycin;\                                      91%; 13 months (1--96 months)                                     (1--18 years)                    94%                                                   3% 5 years\                       None\
                                                                                                        35%                                                                                                                                                                                                                                                  12% 10 years                      and\
                                                                                                                                                                                                                                                                                                                                                                                               6%

  **Studies incorporating clarithromycin**                                                                                                                                                                                                                                                                                                                                                     

   S[hiraishi]{.smallcaps} \[28\]                 21               MAC 100%                             100%; 11 months (2.2--29.1); 100% on clarithromycin;\                                       90%; 6--12 months                                                 35 months^¶^ (6--99)             100%                                                  10% 2 years                       None\
                                                                                                        38%                                                                                                                                                                                                                                                                                    and\
                                                                                                                                                                                                                                                                                                                                                                                               None

   S[hiraishi]{.smallcaps} \[29\]                 11               MAC 91%\                             100%; 57 months  (13--109 months); 100% had clarithromycin;\                                64%; 6--24 months                                                 2 years^¶^ (0.6--17)             100%                                                  9% 2 years                        None\
                                                                   *M.* *abscessus* 9%                  Not reported                                                                                                                                                                                                                                                                           and\
                                                                                                                                                                                                                                                                                                                                                                                               18%

   W[atanabe]{.smallcaps} \[39\]                  22               MAC 100%                             100%; 17 months (2--37 months); 82% on clarithromycin;\                                     100%; 6--35 months                                                46 months^¶^ (6--164)            90%\                                                  Not reported                      None\
                                                                                                        80%^§^                                                                                                                                                                                         100% after antimicrobials                                                               and\
                                                                                                                                                                                                                                                                                                                                                                                               None

   M[itchell]{.smallcaps} \[43\]                  236              MAC 80%\                             100%; 2--6 months;\                                                                         Not reported                                                      Not reported                     100%                                                  Not reported                      2.6%\
                                                                   *M.* *abscessus* 14%                 57% negative sputum prior surgery                                                                                                                                                                                                                                                      and\
                                                                                                                                                                                                                                                                                                                                                                                               2.6%

   K[oh]{.smallcaps} \[40\]                       23               MAC 43%\                             87%; 7.5 months (5--17 months);100% on clarithromycin;\                                     97%; 12 months (6--26 months)                                     14 months^¶^ (IQR 6--11)         100% (in 1--2 months)                                 Not reported                      None\
                                                                   *M.* *abscessus* 52%\                26%                                                                                                                                                                                                                                                                                    and\
                                                                   *M.* *xenopi* 4%                                                                                                                                                                                                                                                                                                            9%

   [van]{.smallcaps} I[ngen]{.smallcaps} \[19\]   8                MAC 87.5%\                           100%; 22 months;\                                                                           50%; 9 months                                                     19 months^\#^                    88%                                                   0% 19 months                      12.5%\
                                                                   *M.* *xenopi* 12.5%                  Not reported                                                                                                                                                                                                                                                                           and\
                                                                                                                                                                                                                                                                                                                                                                                               12.5%

   Y[u]{.smallcaps} \[30\]                        128              MAC 88%\                             100%; at least 2--3 months;\                                                                100%; duration not reported                                       23 months^\#^ (0--70)            84%\                                                  7% 17 months                      None\
                                                                   *M.* *abscessus* or *chelonae* 10%   Not reported                                                                                                                                                                                   97% sputum negative at final follow up at 34 months                                     and\
                                                                                                                                                                                                                                                                                                                                                                                               None

   J[arand]{.smallcaps} \[41\]                    24               *M.* abscessus 100%                  100%; uncertain; % macrolide uncertain;\                                                    100%; duration not separately reported for surgery group          34 months (2--82)^\#^            Uncertain\                                            Never converted or relapsed 35%   Uncertain\
                                                                                                        71%                                                                                                                                                                                            Overall 65%                                                                             and\
                                                                                                                                                                                                                                                                                                                                                                                               17%

   S[hiraishi]{.smallcaps} \[31\]                 60               MAC 92%\                             100%; 14.2 months (3.3--75.2); 100% clarithromycin;\                                        100%; at least 12 months post-surgery or post-sputum conversion   34 months^¶^ (13--70)            100%                                                  3%\                               None\
                                                                   *M.* *abscessus* 5%\                 Not reported                                                                                                                                                                                                                                         34 months                         and\
                                                                   *M.* *gordonae* 1.6%\                                                                                                                                                                                                                                                                                                       None
                                                                   *M.* *xenopi* 1.6%                                                                                                                                                                                                                                                                                                          

   A[sakura]{.smallcaps} \[37\]                   125              MAC 80%\                             94% treatment before and after surgery; 7 months (IQR 6--18 months); 82% clarithromycin;\   94% (before and after);\                                          7.1 years^¶^ (IQR 3.5--10.3)     91%                                                   5% 1 year\                        4%\
                                                                   *M.* *Intracellulare* 8%\            Not reported                                                                                7 months (IQR 6--18 months)                                                                                                                              10% 3 years\                      and\
                                                                   *M.* *abscessus* 5%\                                                                                                                                                                                                                                                                      15% 5 years\                      4%
                                                                   *M.* *kansasi* 3%\                                                                                                                                                                                                                                                                        20% 19 years                      
                                                                   Others 5%                                                                                                                                                                                                                                                                                                                   
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^\#^: mean; ^¶^: median (range); ^+^: 2 patients (7%) suffered late deaths due to unrelated causes; ^§^: only those (5 out of 25) who did not sputum convert were referred on for surgical treatment and joined 17 other patients from another hospital to make up to 22 patients in the cohort.

Surgical outcomes {#s5}
=================

Mortality {#s5a}
---------

Most studies reported no early post-operative deaths \[[@C23], [@C28]--[@C31], [@C34], [@C35], [@C39], [@C40]\]. N[elson]{.smallcaps} *et al.* \[[@C38]\] reported two (7%) deaths out of 28 patients; one died of a myocardial infarction and the second due to acute respiratory failure. M[itchell]{.smallcaps} *et al.* \[[@C43]\] also reported two early post-operative deaths (out of 236 patients; \<1%) with one death secondary to ARDS and another due to bronchopleural fistula with MI.

Long-term mortality varied between 3% and 21% and was mostly due to respiratory failure. Most studies followed patients for 6--8 years, but two studies followed patients for nearly 20 years post-surgery \[[@C34], [@C37]\]. Two case series conducted in the pre-clarithromycin era demonstrated reduced mortality (0% *versus* 10%) in patients managed more aggressively with earlier surgery \[[@C23], [@C44]\]. However, these finding are less relevant today, given that the overall mortality rates associated with surgical treatment of pulmonary NTM disease declined from 7% in the 1980s to \<1% today \[[@C43]\].

Common complications {#s5b}
--------------------

In the studies evaluated, post-operative complication rates averaged 28%, but varied widely across the studies (range 0--63%) and most complications occurred post-pneumonectomy. A[sakura]{.smallcaps} *et al.* \[[@C37]\] found that pneumonectomy, when compared to other resections, was associated with higher rates of post-operative complications with an odds ratio of 4.1 (95% CI 1.6--10.3; p=0.005). Pneumonectomy was generally associated with higher rates of bronchopleural fistula; up to 27% of cases in one series \[[@C29]\]. Bronchial stumps were often reinforced with muscle flaps (latissimus dorsi, serratus anterior or intercostal) and occasionally omental flaps to try to reduce this risk, but its effectiveness is uncertain, and M[itchell]{.smallcaps} *et al.* \[[@C43]\] found that the risk of bronchopleural fistula was associated with positive sputum at the time of surgery. Other complications included lobar atelectasis requiring bronchoscopy, wound infection, wound dehiscence and haemorrhage ([table 3](#TB3){ref-type="table"}).

Risk factors for poor prognosis {#s5c}
-------------------------------

A[sakura]{.smallcaps} *et al.* \[[@C37]\] found that, in addition to pneumonectomy, older age, low BMI and remnant cavitary lesions were predictors of poor prognosis. Sputum clearance was higher after pneumonectomy, but with increased morbidity and unfortunately the characteristics of those who may benefit from a pneumonectomy were not identified \[[@C37]\]. Limited resection was generally associated with better outcome \[[@C35], [@C39]\].

P[omerantz]{.smallcaps} *et al.* \[[@C36]\] compared outcomes of pulmonary resections in those with TB and NTM subjects. Their group found that those infected with NTM had poorer results with higher incidences of complications compared with the TB group. They proposed that this might be due to the older age group of those with NTM disease and the indolent nature of disease resulting in more extensive parenchymal involvement at the time of surgery, resulting in more extensive surgical resections \[[@C36]\]. Low BMI (≤18.5 kg·m^−2^) was associated with worse outcomes (OR 1.91, 95% CI 1.11--3.29) in patients undergoing lung surgery for MDR-TB \[[@C45]\] and pulmonary NTM disease \[[@C37]\].

Sputum clearance {#s5d}
----------------

The sputum clearance rates reported across studies ranged from 84% to 100%; with better conversion rates if antibiotics were continued post-operatively \[[@C38]\]. Excellent long-term clearance rates of 95% at 1 year and 87% at 3 years after surgery have been reported in some recent studies \[[@C28]\]. Relapses may be due to occult bilateral disease or infection of the healthy lung around the time of surgical resection; one patient with initial post-surgery sputum conversion required a second lobectomy in the contralateral lung \[[@C28]\]. Relapse rates of 0--20% have been reported with concomitant antibiotic therapy and follow-up periods of 9 months to 19 years. A[sakura]{.smallcaps} *et al.* \[[@C37]\] showed that the presence of persisting cavitary lesions after surgery is a significant predictor of microbiological recurrence with an adjusted hazard ratio of 6.73 (CI 1.68--22.7; p=0.0095). J[arand]{.smallcaps} *et al.* \[[@C41]\] compared patients with combined antibiotic and surgical therapy compared with antibiotic therapy alone and showed that the surgical group had a significantly higher rates of culture conversion and remained culture negative at 1 year (57% *versus* 28%; p=0.022).

Lung function {#s5e}
-------------

Only one study reported results of lung function after surgery \[[@C39]\]. It showed that vital capacity and forced expiratory volume in 1 s were at 89% and 84% of the pre-operative values, respectively. The study did not assess for ongoing decline after surgery.

Antibiotic treatment {#s6}
====================

Pre-operative {#s6a}
-------------

Despite the introduction of clarithromycin, surgery still assists culture conversion in those who fail medical treatment \[[@C28]\]. Most patients were treated for 6--18 months with multiple antibiotics prior to surgery with some patients on treatment for up to 6 years. Across the studies, sputum conversion with antibiotics alone prior to surgery ranged between 12% and 80% ([table 4](#TB4){ref-type="table"}). E[lkadi]{.smallcaps} *et al.* \[[@C23]\] found that patients on the longest treatment course of antibiotics prior to surgery took longer to achieve sputum clearance post-operatively; which may suggest increased acquisition of drug resistance if surgery is delayed for too long, or simply reflect selection bias. On average, studies reported a delay of ∼14 months from diagnosis before surgery was performed.

Post-operative {#s6b}
--------------

H[attler]{.smallcaps} *et al.* \[[@C25]\] showed that the sputum conversion rate after operative management was 91% compared to 27% with medical treatment alone, while C[orpe]{.smallcaps} \[[@C24]\] found that bacteriological cure was 2--3 times greater with combined surgical and medical treatment; however, both studies were conducted in the pre-clarithromycin era. Most studies continued antibiotic treatment after surgery, which was associated with greater sputum clearance \[[@C39], [@C40]\]. The duration of antibiotic treatment ranged from a few months to several years. Current ATS/IDSA guidelines advocate treatment for 12 months after culture conversion \[[@C12]\], which was mostly achieved following surgery. Some centres recommended treatment for 2 years after pneumonectomy, since stump breakdown or infection of the remaining lung can be fatal \[[@C29]\].

Limitations and future directions {#s6c}
---------------------------------

It is challenging to accurately assess the impact of surgical interventions, since no randomised controlled trials (RCT) have compared the benefits of surgery to antibiotic therapy alone \[[@C46]\]. RCTs are required to draw firm conclusions about the role of surgery in this setting but are problematic due to low patient numbers and variability in the mycobacterial species and drug susceptibility patterns of individual patients. No studies have been performed in children or in patients with CF. Specific to CF, the United States CF Foundation and European CF society urge caution when considering surgical treatment for CF pulmonary NTM disease as localised disease is rare and it is difficult to differentiate NTM changes from the underlying disease process \[[@C46]\]. The studies performed to date have largely focused on subjects with MAC disease and the impact of NTM species on outcomes remains unclear. Hopefully improved standardisation of NTM treatment and identification of candidates for surgery following the publication of consensus guidelines from the ATS/IDSA will facilitate easier comparison of future surgical case series.

Conclusion {#s7}
==========

The results of studies to date suggest that lung surgery may have value in the management of NTM pulmonary disease. However, its role requires further clarification and there must be careful consideration of the risks and benefits. While surgery is associated with low rates of post-operative mortality the long-term mortality and morbidity is highly variable. The value of surgery in children and patients with CF with pulmonary NTM disease remains unclear, but should be considered with caution.

Self-evaluation questions
-------------------------

1.  What is the role of surgery in the treatment of pulmonary NTM disease? a) Surgery is the main treatment for localised pulmonary NTM diseaseb) Surgery has no role in the treatment of pulmonary NTM diseasec) Surgery should be considered as an adjuvant treatment in selected patients with localised pulmonary NTM diseased) Surgery should be only considered in the treatment of pulmonary NTM disease if antibiotic treatments have failed

2.  What initial factors are important to consider when evaluating the role of surgery for the treatment of NTM pulmonary disease? a) Age, sex and BMIb) Localised disease that is amenable to resection in a patient with adequate underlying pulmonary reservec) Localised disease due to *Mycobacterium avium* complex (MAC)d) Irretraceable coughing and recurrent haemoptysis

3.  Which of the statements around the indication for surgery in the treatment of pulmonary NTM disease is [false]{.ul}? a) In the post-macrolide era, most surgical treatment of pulmonary NTM disease was due to medical treatment failureb) Surgery might be indicated to prevent further spread NTM pulmonary infectionc) Haemoptysis is the most frequent indication for surgeryd) At times, surgery might be indicated early to optimise chances of cure

4.  Which of the following statements is true? a) Pneumonectomy is the most common type of surgical procedure usedb) Bronchopulmonary fistulae are the most common major post-operative complication and occur most often after lobectomyc) Post-operative mortality rates are highd) Bronchopulmonary fistulae occur more commonly after pneumonectomy

5.  With regards to post-operative outcomes, which of the following statements is [false]{.ul}? a) Sputum clearance is high post-operativelyb) Sputum clearance improves with pre- and post-operative antibiotic treatmentc) Persisting cavitary lesions after surgery is a significant predictor of microbiological recurrence of diseased) Antibiotics can be reassuringly ceased after sputum clearance post-pneumonectomy

Suggested answers
-----------------

1.  c\.

2.  b\.

3.  c\.

4.  d\.

5.  d\.
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